Is Thymosin Alpha-1 Legal in Alabama? How to Access It Legally
HealthRX.com
No lawful route to thymosin alpha-1 is established federally
Key numbers
- 4 yes and 17 noPharmacy Compounding Advisory Committee vote on the free base and acetate forms, December 4, 2024Source: fda.gov, as cited Nov 7, 2026
- 1.6 mgItalian Zadaxin label dose per injection, not a US prescribing standardSource: fda.gov, as cited Nov 7, 2026
- 4 weeksLength of the Italian Zadaxin label course, not a US prescribing standardSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA approval / Not approved; a Drugs@FDA search found no US application, and four US orphan drug designations are not approvals [1].
- Approved outside the US / Italy, India and Hong Kong (per FDA); Zadaxin is sold as 1.6 mg vials [1].
- FDA list for state-licensed pharmacies / Not in any of the three categories [2].
- FDA list for outsourcing facilities / Category 3, 'nominated without adequate support' [3].
- FDA advisory committee vote / 4 yes, 17 no, with no abstentions, on December 4, 2024 [4].
- HHS peptide enforcement policy / Not among the six peptides in the October 2026 draft [5].
- US-approved dose / None exists [1].
Is thymosin alpha-1 legal in Alabama?
Thymosin alpha-1 has no FDA approval in the US [1]. It is in none of the three categories on FDA's list for state-licensed pharmacies and physicians [2], and it is in category 3, 'nominated without adequate support,' on FDA's list for outsourcing facilities [3]. FDA's category 1 policy, under which FDA generally takes no action against compounders who meet conditions, does not apply to it.
No Alabama rule naming it was identified, so Alabama-specific pharmacy and prescribing requirements are not established here.
Questions worth asking
What is its federal status?
On FDA's page for substances that may present significant safety risks, thymosin alpha-1 is in the 'nominated but withdrawn' table: it had been in category 2 and came off after the nominators withdrew [6]. FDA's concerns remain posted, including 'significant risk for immunogenicity for certain routes of administration' and peptide-impurity and characterization problems [6].
A Drugs@FDA search found no US application for thymosin alpha-1. Its four US orphan drug designations are a separate process and not an approval [1]. FDA lists national authorizations in Italy, India and Hong Kong [1]. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions [4]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
Can a pharmacy dispense it on a prescription?
Thymosin alpha-1 is absent from the categories for state-licensed pharmacies and physicians, and it is in category 3 for outsourcing facilities [2][3]. No FDA or HHS action allowing it to be compounded was found. There is no US-approved dose [1].
For context only, the Italian Zadaxin label uses 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1]. Zadaxin is a finished injection and is not interchangeable with bulk thymosin alpha-1 powder [1]. The Italian regimen is not a US prescribing standard and is not a way to obtain the drug in Alabama.
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in Alabama?
Is thymosin alpha-1 FDA-approved?
Did FDA consider allowing it to be compounded?
Is there a standard dose?
References
Show all 6 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Department of Health and Human Services. HHS 503A peptide enforcement discretion policy, Appendix B
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.